Rothschild Investment Corp IL Sells 400 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Rothschild Investment Corp IL decreased its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 2.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,219 shares of the biotechnology company’s stock after selling 400 shares during the period. Rothschild Investment Corp IL’s holdings in BioMarin Pharmaceutical were worth $1,161,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of BMRN. BB&T Securities LLC boosted its stake in shares of BioMarin Pharmaceutical by 4.0% in the 2nd quarter. BB&T Securities LLC now owns 3,447 shares of the biotechnology company’s stock valued at $295,000 after purchasing an additional 132 shares in the last quarter. Avestar Capital LLC boosted its stake in shares of BioMarin Pharmaceutical by 36.9% in the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 202 shares in the last quarter. First Mercantile Trust Co. boosted its stake in shares of BioMarin Pharmaceutical by 2.6% in the 2nd quarter. First Mercantile Trust Co. now owns 8,116 shares of the biotechnology company’s stock valued at $695,000 after purchasing an additional 206 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of BioMarin Pharmaceutical by 35.0% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 1,115 shares of the biotechnology company’s stock valued at $98,000 after purchasing an additional 289 shares in the last quarter. Finally, Doyle Wealth Management purchased a new stake in shares of BioMarin Pharmaceutical in the 2nd quarter valued at $26,000. 97.93% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director V Bryan Lawlis sold 3,750 shares of the firm’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $74.47, for a total value of $279,262.50. Following the completion of the sale, the director now directly owns 27,340 shares of the company’s stock, valued at approximately $2,036,009.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.90% of the company’s stock.

Shares of BMRN opened at $67.36 on Friday. The stock has a market capitalization of $11.67 billion, a P/E ratio of -204.12 and a beta of 1.31. The company has a quick ratio of 2.79, a current ratio of 4.11 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $71.68 and a two-hundred day simple moving average of $80.74. BioMarin Pharmaceutical Inc. has a twelve month low of $62.88 and a twelve month high of $106.74.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its earnings results on Thursday, August 1st. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.16). BioMarin Pharmaceutical had a negative return on equity of 3.12% and a negative net margin of 7.19%. The company had revenue of $388.00 million during the quarter, compared to analysts’ expectations of $415.03 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 4.0% on a year-over-year basis. Sell-side analysts expect that BioMarin Pharmaceutical Inc. will post -0.03 EPS for the current fiscal year.

A number of equities research analysts have recently issued reports on the stock. Piper Jaffray Companies set a $120.00 price objective on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Friday, September 13th. Wedbush set a $128.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Thursday, September 26th. Stifel Nicolaus set a $108.00 price target on shares of BioMarin Pharmaceutical and gave the company a “buy” rating in a research report on Friday, September 13th. JPMorgan Chase & Co. reissued a “buy” rating and set a $133.00 price target on shares of BioMarin Pharmaceutical in a research report on Monday, August 5th. Finally, BidaskClub cut shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Friday, September 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and thirteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $115.33.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.

Featured Article: Gap Down Stocks

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit